Table 4.
Relationship between Baseline Characteristics and Risk of Cardiovascular Hospitalization
| Amiodarone | Rate | Sotalol | Rate | Class 1C | Rate | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (PSM) (N=729) |
(PSM) (N=729) |
(PSM) (N=606) |
(PSM) (N=606) |
(PSM) (N=268) |
(PSM) (N=268) |
|||||||||||
| Age - yr | 70.3 ± 9.21 | 70.26 ± 9.21 | 69.7 ± 8.79 | 69.67 ± 8.79 | 0.212 | 69.6 ± 8.8+ | 69.56 ± 8.83 | 70.5 ± 8.4 | 70.48 ± 8.35 | 0.061* | 68.6 ± 8.9 | 68.64 ± 8.93 | 68.6 ± 9.3 | 68.58 ± 9.33 | 0.94 | |
| Female Sex - no. (%) | 238 (32.6%) | 238 (32.6%) | 282 (38.7%)* | 282 (38.7%) | 0.016* | 227 (37.5%) | 227 (37.5%) | 234 (38.6%) | 234 (38.6%) | 0.679 | 140 (52.2%) | 140 (52.2%) | 144 (53.7%) | 144 (53.7%) | 0.729 | |
| Minority Group - no. (%) | 78 (10.7%) | 78 (10.7%) | 98 (13.4%) | 98 (13.4%) | 0.108 | 57 (9.4%) | 57 (9.4%) | 70 (11.6%) | 70 (11.6%) | 0.223 | 24 (9.0%) | 24 (9.0%) | 23 (8.6%) | 23 (8.6%) | 0.879 | |
| CAD (MI, angina etc.) | 247 (33.9%) | 247 (33.9%) | 228 (31.3%) | 228 (31.3%) | 0.921 | 158 (26.1%) | 158 (26.1%) | 165 (27.2%) | 165 (27.2%) | 0.742 | 31 (11.6%) | 31 (11.6%) | 28 (10.4%) | 28 (10.4%) | 0.655 | |
| Dilated Cardiomyopathy | 52 (7.1%) | 52 (7.1%) | 53 (7.3%) | 53 (7.3%) | 20 (3.3%) | 20 (3.3%) | 22 (3.6%) | 22 (3.6%) | 5 (1.9%) | 5 (1.9%) | 5 (1.9%) | 5 (1.9%) | ||||
| Hypertension | 342 (46.9%) | 342 (46.9%) | 351 (48.1%) | 351 (48.1%) | 315 (52.0%) | 315 (52.0%) | 291 (48.0%) | 291 (48.0%) | 156 (58.2%) | 156 (58.2%) | 154 (57.5%) | 154 (57.5%) | ||||
| Valvular Heart Disease | 28 (3.8%) | 28 (3.8%) | 30 (4.1%) | 30 (4.1%) | 34 (5.6%) | 34 (5.6%) | 34 (5.6%) | 34 (5.6%) | 15 (5.6%) | 15 (5.6%) | 9 (3.4%) | 9 (3.4%) | ||||
| No Apparent Heart Disease | 53 (7.3%) | 53 (7.3%) | 58 (8.0%) | 58 (8.0%) | 70 (11.6%) | 70 (11.6%) | 81 (13.4%) | 81 (13.4%) | 60 (22.4%) | 60 (22.4%) | 69 (25.7%) | 69 (25.7%) | ||||
| History of CHF - no. (%) | 221 (30.3%) | 221 (30.3%) | 223 (30.6%) | 223 (30.6%) | 0.909 | 112 (18.5%) | 112 (18.5%) | 121 (20.0%) | 121 (20.0%) | 0.512 | 24 (9.0%) | 24 (9.0%) | 27 (10.1%) | 27 (10.1%) | 0.659 | |
| Qualifying AF >2d - no. (%) | 525 (72.1%) | 525 (72.1%) | 519 (71.2%) | 519 (71.2%) | 0.696 | 406 (67.0%) | 406 (67.0%) | 410 (67.7%) | 410 (67.7%) | 0.806 | 172 (64.2%) | 172 (64.2%) | 175 (65.3%) | 175 (65.3%) | 0.786 | |
| First Episode of AF -no.(%) | 254 (34.8%) | 254 (34.8%) | 260 (36.6%) | 260 (36.6%) | 0.482 | 214 (35.3%) | 214 (35.3%) | 223 (37.9%) | 223 (37.9%) | 0.349 | 73 (27.2%) | 73 (27.2%) | 78 (29.7%) | 78 (29.7%) | 0.537 | |
| Prior Failure of AAD - no. (%) | 139 (19.1%) | 139 (19.1%) | 146 (20.0%) | 146 (20.0%) | 0.644 | 70 (11.6%) | 70 (11.6%) | 83 (13.7%) | 83 (13.7%) | 0.261 | 69 (25.7%) | 69 (25.7%) | 60 (22.4%) | 60 (22.4%) | 0.363 | |
| Normal LA Size - no. (%) | 184 (33.5%) | 184 (33.5%) | 196 (36.6%) | 196 (36.6%) | 0.282 | 172 (35.9%) | 172 (35.9%) | 175 (36.1%) | 175 (36.1%) | 0.955 | 90 (41.9%) | 90 (41.9%) | 94 (43.1%) | 94 (43.1%) | 0.791 | |
| Mean LVEF (%) | 48.7 ±16.9 | 48.66 ±16.91 | 49.4 ±14.8 | 49.40 ±14.84 | 0.709 | 56.7 ±11.0 | 56.74 ±11.03 | 57.4 ±12.1 | 57.39 ±12.06 | 0.64 | 61.4 ± 8.4 | 61.39 ± 8.36 | 58.5 ±11.6 | 58.51 ±11.58 | 0.081* | |
| CCS Class | - No Angina | 636 (87.2%) | 636 (87.2%) | 656 (90.0%) | 637 (87.4%) | 0.976 | 539 (88.9%)* | 539 (88.9%) | 564 (93.1%) | 558 (92.1%) | 0.122 | 258 (96.3%) | 258 (96.3%) | 259 (96.6%) | 256 (95.5%) | 0.897 |
| 62 (8.5%) | 60 (8.2%) | 56 (9.2%) | 37 (6.1%) | 7 (2.6%) | 8 (3.0%) | |||||||||||
| - Class I | 62 (8.5%) | 49 (6.7%) | 56 (9.2%) | 31 (5.1%) | 7 (2.6%) | 4 (1.5%) | ||||||||||
| - Class ≥ II | 31 (4.3%) | 31 (4.3%) | 24 (3.3% | 32 (4.4%) | 11 (1.8%) | 11 (1.8%) | 11 (1.8%) | 11 (1.8%) | 3 (1.1%) | 3 (1.1%) | 5 (1.9%) | 4 (1.5%) | ||||
| NYHA Class | - No CHF | 532 (73.0%) | 532 (73.0%) | 539 (73.9%)+ | 541 (74.2%) | 0.095* | 526 (86.8%) | 526 (86.8%) | 527 (87.0%) | 517 (85.3%) | 0.861 | 240 (89.6%)+ | 240 (89.6%) | 248 (92.5%) | 242 (90.3%) | 0.853 |
| 96 (13.2%) | 81 (11.1%) | 70 (11.6%) | 76 (12.5%) | 19 (7.1%) | 16 (6.0%) | |||||||||||
| - Class I | 96 (13.2%) | 81 (11.1%) | 70 (11.6%) | 58 (9.6%) | 19 (7.1%) | 13 (4.9%) | ||||||||||
| - Class II | 71 (9.7%) | 71 (9.7%) | 91 (12.5%) | 89 (12.2%) | 9 (1.5%) | 9 (1.5%) | 19 (3.1%) | 12 (2.0%) | 9 (3.4%) | 9 (3.4%) | 4 (1.5%) | 10 (3.7%) | ||||
| - Class III | 30 (4.1%) | 30 (4.1%) | 18 (2.5%) | 18 (2.5%) | 1 (0.2%) | 1 (0.2%) | 2 (0.3%) | 1 (0.2%) | 0 (0.0%) | 3 (1.1%) | ||||||
Abbreviations: Amio - amiodarone